Artelo Biosciences (ARTL) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$2.4M

Net income growth (year over year)

+24.65%

Net margin

—

Return on equity

−705.71%

EPS (trailing twelve months)

−$36.11

Book value per share

$10.74

P/E (trailing twelve months)

—

Price to book

0.33

Debt to assets

22.64%

Payout ratio

—

Dividend yield

—

Company profile

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

• How do I buy stock in Artelo Biosciences (ARTL)?

  ARTL trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.